Panasonic Sets New Standard for Decontamination with MCO-19AIC UVH
Independent study comparing H2O2 decontamination method with high heat sterilization offers 8x faster sterilization and a 6 log reduction with 100% kill rate
CHICAGO, March 13, 2013 /PRNewswire-iReach/ — Panasonic Healthcare Company of North America announced that a new independent study has found the Panasonic H2O2 decontamination process to be very effective for cell culture incubators, providing a complete decontamination process in less than three hours. The independent study, performed by Charles River Laboratories, tested the effectiveness of H2O2 decontamination offered by the Panasonic MCO-19 AIC Sterisonic(®) UVH cell culture incubator against the industry leading brands with dry heat and moist heat sterilization techniques.
The results of the study have been published in a Panasonic white paper available at http://www.sterisonich2o2.com.
“The Panasonic MCO-19AIC UVH sets a new standard for advanced sterilization and decontamination cycle time to return the incubator to service significantly faster, allowing increased productivity for researchers and clinicians in the research and Good Manufacturing Practices (GMP) environments,” said Deepak Mistry, Senior Manager, Strategic Development and Marketing at Panasonic.
The study compared the Panasonic MCO-19AIC Sterisonic(®) UVH cell culture incubator against two models, one using dry heat sterilization and the other using moist heat sterilization. While all the three incubators in the study showed complete bioburden reduction of each organism tested, Panasonic’s incubator demonstrated an effective reduction of nearly the same or, in some cases, a greater amount of bioburden in just 2 hours when compared to the 10-12 hour and 25 hour cycles required by the other incubators, based upon the viability of the organisms at room temperature over the elapsed sterilization times.
In an industry where both decontamination and equipment operation time are critical, the Panasonic MCO-19AIC UVH has been designed to stay up and running by offering shorter and equally effective decontamination techniques. The incubator is suitable for a wide array of demanding and highly regulated applications in the biomedical, pharmaceutical, medical research and clinical laboratory settings, representing years of research, development and component testing. Prior to the independent test, the use of H2O2 sterilization in biological safety cabinets and
barrier isolators was considered a popular alternative to ethylene oxide (EtO), and viewed as a logical and safe method for sterilization. Panasonic’s incubator has a documented two-hour in situ H2O2 sequence and features interior components with a CO2 sampling loop that are sterilized in situ with no additional need for removal or separate autoclaving.
About Panasonic Healthcare Company of North America
Based in Secaucus, NJ, Panasonic Healthcare Company of North America is a division of Panasonic Corporation of North America, the principal North American subsidiary of Panasonic Corporation (NYSE:PC). The company provides innovative technological solutions for the needs of customers in the healthcare and life science markets. As a leader in the technology industry, the company offers a wide range of healthcare related products, as well as automation equipment for pharmaceutical, biomedical, and other life science applications.
For additional information, please visit http://www.panasonic.com/business-solutions/healthcare-technology-solutions.asp
Media Contact: Aaron Fowles, Panasonic Corporation of North America, 619-661-2223, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Panasonic Healthcare Company of North America